Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3041-3060 of 3,900 trials

Pancreatic and Bile Duct Cancer: 68Ga-FAPI-46 PET Imaging Study

We are testing a new imaging method to better visualize pancreatic and bile duct cancers. This study aims to see how accurately it detects cancer and monitors treatment response.

Cholangiocarcinoma (Bile Duct Cancer)Pancreatic Carcinoma (Pancreatic Cancer)>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

GA2 Sporozoites with Adjuvants: Immune Response Study

We are exploring whether combining GA2 sporozoites with adjuvants can improve immune responses. This study aims to understand its potential benefits for participants.

Falciparum MalariaSafety phase (I)Infectious Diseases

Bleeding Treatment in Thrombocytopenic Patients: FORMAT Study

We are studying whether adding fibrinogen to platelet transfusions helps patients with low platelet counts after chemotherapy stop bleeding. This trial will evaluate the effectiveness and safety of this treatment approach.

Blood Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematology

Friedreich Ataxia: Vatiquinone Safety Study

We are studying the long-term safety of vatiquinone in patients with Friedreich Ataxia who have previously used this medication. We aim to see how it affects their symptoms over time.

Friedreich's Ataxia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurology

Rheumatoid Arthritis: GS-0151 Treatment Study

We are investigating a new medication, GS-0151, for people with rheumatoid arthritis. The goal is to see how it may help manage symptoms and improve quality of life.

Rheumatoid Arthritis1-2 yearsSafety phase (I)Internal MedicineRheumatology

Metastatic Colorectal Cancer: JNJ-89402638 Study

We are testing a new drug, JNJ-89402638, for patients with metastatic colorectal cancer. This study aims to evaluate its safety and how it may help in treating this advanced stage of cancer.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)Oncology

Type 2 Diabetes: Personalized Treatment Study

We are exploring how different diabetes medications work for patients based on their insulin response. The goal is to find biomarkers that help tailor treatments for better management of type 2 diabetes.

Type 2 Diabetes1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyInternal Medicine

Erlotinib Distribution Study

We are exploring how drug transporters affect the distribution of erlotinib in the brain and other organs in humans. This research may help improve treatment strategies for patients using this medication.

Cancer>2 yearsSafety phase (I)Oncology

Rectal Cancer: REGorafenib and Nivolumab Treatment

We are studying a new treatment combining REGorafenib and Nivolumab with short-course radiotherapy for patients with intermediate-risk rectal cancer. The aim is to see if this approach improves treatment response and safety before surgery.

Locally-advanced Rectal Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Clenbuterol for Spinal and Bulbar Muscular Atrophy (SBMA)

We are studying whether clenbuterol can help patients with SBMA manage their symptoms. We will also look at how well patients tolerate the treatment over time.

Spinal and Bulbar Muscular Atrophy6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesInternal MedicineNeurology

Clebopride for the Treatment of Rumination Syndrome

We are studying whether clebopride can improve symptoms in people suspected of having rumination syndrome. The trial compares its effects to a placebo to see how well it works.

Rumination Syndrome≤3 monthsMonitoring phase (IV)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Bipolar Disorder: Low-Dose Aspirin Study

We are investigating whether adding low-dose aspirin to standard treatment helps improve symptoms in patients with bipolar disorder. This study aims to assess both the effectiveness and safety of this approach.

Bipolar Disorder1-2 yearsEfficacy phase (II)Standard MedicinesPartially RemotePsychiatry

Melanoma with Brain Metastases: Immunotherapy Study

We are studying the effects of immunotherapy in melanoma patients with brain metastases who are also receiving steroid treatment. Our goal is to see if this combination improves outcomes compared to standard care.

Malignant Melanoma of Skin1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Clofarabine for Advanced Urothelial Carcinoma

We are studying the safety and effectiveness of Clofarabine in patients with locally advanced or metastatic urothelial carcinoma. The trial aims to find the highest dose that can be tolerated while assessing how well the treatment works.

Bladder Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Chronic Kidney Disease: Optimizing Tacrolimus Dosage with Genetic Testing

We are studying whether a genetic testing strategy can help tailor tacrolimus dosing for patients with chronic kidney disease before kidney transplantation. This may improve treatment outcomes and reduce side effects.

Kidney Transplant1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesInternal MedicineNephrology

Diabetic Cardiovascular Autonomic Neuropathy: The FibroCAN Study

We are investigating whether finerenone can help improve heart function and reduce nerve damage in people with type 2 diabetes and early-stage cardiovascular autonomic neuropathy. This study compares the treatment to a placebo to assess its effects.

Diabetic Cardiovascular Autonomic Neuropathy1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyEndocrinologyNeurology

Activated T-Cells for Graft vs Host Disease After Stem Cell Transplant

We are testing a new treatment using activated regulatory T-cells in patients shortly after stem cell transplantation. The aim is to see if it can safely reduce the risk and severity of acute graft vs host disease.

LeukaemiaAcute graft versus host disease1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

RSV Hospitalization Prevention: Abrysvo® Vaccine Study

We are studying whether the Abrysvo® vaccine can help prevent hospitalizations from RSV in adults aged 18 and older, especially those 60 and above. This research aims to improve respiratory health outcomes in older adults.

RSV Infection6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Advanced Solid Tumors: BMS-986482 Study

We are investigating the safety and dosage of BMS-986482 alone or with other therapies for patients with advanced solid tumors. This study aims to understand how well it works in combination with existing treatments.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Nodal T Cell Lymphoma: Duvelisib vs. Gemcitabine or Bendamustine

We are studying whether duvelisib can improve outcomes for patients with relapsed or refractory nodal T cell lymphoma. This trial compares its effects to standard treatments like gemcitabine or bendamustine.

Refractory Adult T-cell LymphomaRelapsed/Refractory Nodal T Cell Lymphoma with TFH Phenotype>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology